Celldex Therapeutics (CLDX)

Executive Summary

Celldex Therapeutics (NASDAQ: CLDX) is a clinical-stage biotech focused on antibody therapeutics for cancer and inflammatory diseases. Its lead asset, barzolvolimab (CDX-0159), a monoclonal antibody targeting the KIT receptor, has shown promising results in chronic urticaria and is being developed for atopic dermatitis and prurigo nodularis. Positive Phase 2 data in chronic inducible urticaria (2025) de-risked the program, leading to planned Phase 3 trials. With a market cap ~$2.3B, Celldex is positioned to address large dermatology markets. The company also has early-stage oncology pipeline (CDX-1140, CDX-527) but near-term value hinges on barzolvolimab's progress in inflammatory indications. Strategic partnerships or financing could further support development.

Upcoming Catalysts (preview)

• Q3 2026Phase 3 initiation for barzolvolimab in chronic spontaneous urticaria90% success
• Q4 2026Top-line Phase 2 data for barzolvolimab in atopic dermatitis65% success
• 2026Partnership/licensing deal for barzolvolimab ex-U.S. rights50% success